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Abstract
Background: Although it is known that coronary computed tomographic angiography (CCTA) offers highly negative
predictive value to exclude obstructive coronary lesions, the plaque pattern on CCTA has not been fully understood.
The purpose of this study was to explore the difference of the plaque patterns on CCTA and to assess the
cardiovascular risks in healthy subjects.
Methods: A total of 3914 subjects (mean age: 55 ± 10 years, M : F = 2649 : 1265) who underwent CCTA for health check-
up between January 2009 and December 2012 were enrolled. According to coronary artery calcium score (CACS) and
plaque pattern on CCTA, subjects were categorized into four groups (group 1: normal; group 2: “non-calcified” plaque;
group 3: “calcified” plaque; group 4: mixed plaque). We analyzed cardiovascular risks and Framingham risk score (FRS)
among the groups.
Results: The incidence of each group was group 1 in 55.0% (2152/3914), group 2 in 5.1% (200/3914), group 3 in 8.2%
(319/3914), and group 4 in 7.2% (280/3914), respectively. There was no difference of FRS among the groups (6.4 ± 6.4%;
6.5 ± 4.6%; 8.2 ± 5.8%; 7.7 ± 5.7% p = 0.086). In multivariate analysis, HbA1c (OR = 2.285; 95%CI = 1.029 - 5.071; p = 0.042) in
group 2; age (OR = 1.115; 95%CI = 1.034 - 1.202; p = 0.005) and smoking status (OR = 3.386; 95%CI = 1.124 - 10.202; p = 0.
030) in group 3; and age (OR = 1.054; 95%CI = 1.011 - 1.099; p = 0.014) and hypertension (OR = 3.087; 95%CI = 1.536 - 6.
202; p = 0.001) in group 4 were independent factors.
Conclusions: Our data suggest that more individualized therapy for reduction of cardiovascular risks associated with
plaque pattern on CCTA could be considered in healthy subjects.
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Background
Now it is well known that coronary artery disease
(CAD) is the leading mortality cause due to sudden
death or myocardial infarction in healthy subjects and a
major public health problem in the world [1]. Therefore,
it is potentially important that the endeavor to identify
subclinical coronary atherosclerosis can lead to reduc-
tion in the rate of cardiovascular events. Although
Framingham risk score (FRS), 10-year risk for coronary
heart disease (CHD) represents a very useful diagnostic
tool, there are some limitations for the estimation of the
risk of cardiovascular morbidity and mortality such as
overestimation in a low-risk population or underestima-
tion the risk in a high-risk population [2].
Conventional invasive coronary angiography has been
the standard method for diagnosing CAD [3, 4]. In
addition, the recent multidetector coronary computed
tomographic angiography (CCTA) using dual-source
computed tomography (DSCT) was introduced as a use-
ful, non-invasive tool for the evaluation of coronary
atherosclerosis and the prediction of cardiovascular
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morbidity [5, 6]. However, the screening of coronary
artery calcium score (CACS) using CCTA should not be
recommended in asymptomatic individuals with low-risk
(0 to 1 risk factor or a 10-year risk <10%) or high-risk
(CHD risk equivalents or a 10-year risk >20%) according
to Framingham criteria, but considered useful in patients
with intermediate- risk (more than two risk factors or a
10-year risk 10-20%) [7, 8]. Nevertheless, CACS has not
only an excellent negative predictive value to exclude
the presence of significant CAD [9, 10], but provides
also more important prognostic information for
cardiovascular risk stratification than the biomarker,
such as C-reactive protein [11, 12].
Until now, the usefulness of CCTA for estimating and
predicting of subclinical coronary atherosclerosis in
healthy subjects has not been well established, although
past studies mostly included symptomatic patients with
significant or obstructive CAD including acute coronary
syndrome [13, 14]. The purpose of this study was to
explore the difference of the plaque patterns on CCTA
such as “non-calcified” or “calcified” plaque and to assess
the cardiovascular risks in healthy subjects.
Methods
Study population
Between January 2009 and December 2012, a total of
3914 subjects (mean age: 55 ± 10 years, M : F = 2649 :
1265) who underwent CCTA for health check-up at the
Heath Promotion Center of Seoul St. Mary’s Hospital
(The Catholic University, Seoul, Korea), were enrolled.
Criteria for exclusion included: the patients (1) who
underwent prior coronary artery bypass graft (CABG: n
= 4, 0.10%); (2) who underwent prior percutaneous
coronary intervention (PCI: n = 39, 1.0%) using stents, or
the subjects (3) with irregular heartbeats (e.g., atrial
fibrillation), very severe obesity (body mass index; BMI
≥40 kg/m2) [15], or inability to comply with instructions
for breath holding; or (4) with CACS >10 or more than
mild (≥25%) luminal stenosis represented as group 5, as
a dropout (Fig. 1) [16–18].
According to the coronary artery calcium score
(CACS) and plaque pattern on CCTA, we assigned as a
inclusion criteria, subjects were categorized into four
groups: (1) group 1 (e.g., normal lumen / no plaque)
represented as “normal” coronary arteries: CACS = 0 &
normal CCTA; (2) group 2 (e.g., <25% lumen / “non-cal-
cified or soft” plaque): CACS = 0 & CCTA of minimal
disease (luminal diameter <25%); (3) group 3 (e.g., <25%
lumen or plaque with negligible impact on lumen / “cal-
cified” plaque): CACS >0 & normal CCTA (CACS rage
in our data: 0.42–7.9); (4) group 4 (e.g., <25% lumen /
“mixed” plaque): CACS ≤ 10 & CCTA of minimal disease
(luminal diameter <25%) who met the inclusion criteria,
were included in the study [16–18]. After ruling out the
subjects with CACS >10 or more than mild (≥25%) lu-
minal stenosis represented as group 5 in present study, we
compared FRS and the other traditional cardiovascular
risks among the four groups.
This study was approved by the Institutional Review
Committee of St Mary’s Hospital, the Catholic University
of Korea and conducted in agreement with the Declaration
of Helsinki. The participants were informed of the investi-
gative nature of the study and written informed consent
was obtained before enrollment (XC11RIMI0091S).
Anthropometric parameters
Each participant also underwent a complete physical
examination including anthropometric measurements.
Heights were measured to the nearest 0.1 cm with a
portable stadiometer (InBody 720; Biospace Ltd.,
Seoul, Korea) and body weights were measured to the
nearest 0.1 kg using a digital scale wearing a stan-
dardized health check-up gown. BMI was calculated
as the weight in kilograms, divided by the height in
Fig. 1 Flow diagram. Group 1 (e.g., normal lumen / no plaque) represented as “normal” coronary arteries: CACS = 0 & normal CCTA; Group 2
(e.g., <25% lumen / “non-calcified or soft” plaque): CACS = 0 & CCTA of minimal disease (luminal diameter <25%); Group 3 (e.g., <25% lumen or
plaque with negligible impact on lumen / “calcified” plaque): CACS >0 & normal CCTA (CACS rage in our data: 0.42–7.9); Group 4 (e.g., <25%
lumen / “mixed” plaque): CACS≤ 10 & CCTA of minimal disease (luminal diameter <25%); Group 5 the subjects with CACS >10 or more than mild
(≥25%) luminal stenosis [16–18]. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; BMI, body mass index; CACS,
coronary artery calcium score; CCTA, coronary computed tomographic angiography
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meters squared. Systolic blood pressure (BP), diastolic
BP, and heart rate were measured using an automatic
sphygmomanometer (BP203RV-II; Nippon Colin, Komaki,
Japan) with subjects in a seated position after resting
quietly for 10 min.
Biochemical parameters
Blood samples were taken at health check-up day.
The lipid profile, including total cholesterol, trigly-
ceride, high-density lipoprotein cholesterol (HDL-
cholesterol), and low-density lipoprotein cholesterol
(LDL-cholesterol) levels were measured using enzym-
atic method by an automatic analyzer (7600-210;
Hitachi Medical Corp., Tokyo, Japan). HbA1c was
measured by G8 HbA1c analyzer (Tosoh Corporation,
Tokyo, Japan). The biochemistry including fasting
blood glucose and C-reactive protein from blood sam-
ples were measured by a biochemistry analyzer (7600-
210; Hitachi Medical Corp., Tokyo, Japan).
Framingham risk score
The 10-year risk for myocardial infarction and coron-
ary death is estimated from total points and all par-
ticipants were categorized into three different CHD
risk groups according to the National Cholesterol
Education Program (NCEP) guidelines: (1) low-risk
(10-year risk <10%); (2) moderate- or intermediate-
risk (10-year risk 10–20%); and (3) high-risk group
(10-year risk >20%) [19].
Coronary artery calcium score assessment
We measured coronary artery calcification with a DSCT
(SOMATOM Definition; Siemens Healthcare, Forchheim,
Germany). The participants did not receive additional pre-
medications, such as β-blockers, for control of their heart
rate. DSCT parameters were as follows: tube voltage = 120
kVp, gantry rotation time = 0.33 s, slice collimation = 64 ×
0.6 mm, reconstruction slice width = 0.75 mm, reconstruc-
tion slice interval = 0.4 mm, kernel = B26f, field of view =
25 cm. Eighty mL of contrast agent (Iohexol, IOBRIX INJ
300; Tae Joon Pharm. Ind. Co., Ltd, Seoul, Korea) using a
dual-head power injector (CT Stellant; Medrad Inc., India-
nola, Pennsylvania, USA) was injected intravenously at
5 mL/s for 16 s.
All post-processing examinations were performed
using retrospective electrocardiography (ECG)-gating.
Scans were analyzed by consensus of two observers
(YS Choi and JI Jung) with more than 3 years ex-
perience in cardiac CT imaging. CACS for vascular
calcification were analyzed using a software (syngo.CT
CaScoring; Siemens Healthcare; Forcheim, Germany).
For defining the quantity of coronary calcium,
Agatston score, standard parameter, was used as the
product of the area of calcification per coronary
tomographic segment and a factor rated 1 through 4 dic-
tated by the maximal calcium x-ray density in that seg-
ment, as described elsewhere [20]. The sum of all lesion
scores for each major coronary artery including left main
(LM), left anterior descending artery (LAD), left circum-
flex artery (LCX), and right coronary artery (RCA) was
used to generate the total CACS.
CCTA image acquisition and analysis
Reconstructed DSCT angiograms were analyzed on three-
dimensional workstation (Advantage Windows Worksta-
tion 4.3, GE Healthcare, Milwaukee, Wisconsin, USA),
using a software (Card IQ; GE Healthcare, Milwaukee.
Wisconsin, USA). From a previously described standard
American Heart Association (AHA) segmentation model
[21], DSCT angiographic analysis was performed by YS
Choi and JI Jung without knowledge of clinical findings.
Two experienced intra- and inter- observers visually
assessed each coronary segment using standard transaxial
(2-dimensional) image stacks (“raw data”), oblique multi-
planar reconstructions (MPRs), oblique maximum inten-
sity projections (MIPs), curved multiplanar reformations
(cMPRs), and volume-rendering (3-dimensional) tech-
nique (VRT) reconstructions [22], and performed manual
computed tomography– based quantitative coronary ana-
lysis (CTQCA) using the most representative longitudinal
image and a simplified calculation that estimates normal
tapering of the coronary artery based on the initial method
described by Reiber et al [23]. Maximal diameter stenosis
severity was visually determined and were categorized as 0
to 5 (0 = no stenosis, 1 = 1% to 24%, 2 = 25% to 49%, 3 =
50% to 69%, 4 = 70% to 89%, 5 = 90% to 100%) [16–18].
Statistical analysis
All data are expressed as mean ± standard deviation
(SD) for continuous variables and as a frequency per-
centage for categorical variables and statistical analysis
was performed using the SAS statistical software ver-
sion 9.2 (SAS Institute, Cary, NC, USA). Analysis
among the groups for continuous variables was per-
formed using ANOVA test and analysis of categorical
data was performed using the Tukey’s b-test as a
post-hoc t-test. Analysis between the two groups was
performed using unpaired t-test for continuous vari-
ables and chi-squared test for categorical data. The
clinical variables related to FRS were assessed using
Pearson correlation coefficient. To identify independ-
ent factors associated with the plaque pattern on
CCTA, we used multiple logistic regression analysis
and calculated odds ratios (OR) and 95% confidence
intervals (95% CI). All statistical tests were 2-tailed
and p <0.05 was considered statistically significant.
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Results
Clinical characteristics
The mean age of a total of 3914 participants was 55 ±
10 years; there were more male (n = 2649) than female
(n = 1265) subjects. A total of 977 of 1265 (78.8%) female
subjects were postmenopausal. The prevalence of hyper-
tension, diabetes mellitus, dyslipidemia, familial history
of cardiovascular risk and current smoking state were
32.5, 12.8, 16.0, 84.2 and 20.3%, respectively.
Mean total CACS was 52 ± 200 mm3. Average scan
heart rate was 67 ± 10 beats per minute.
Of 2951/3914 (75.4%) subjects enrolled for this study,
the prevalence of each group according to the CACS
and plaque pattern on CCTA was group 1 in 55.0%
(2152/3914), group 2 in 5.1% (200/3914), group 3 in
8.2% (319/3914), and group 4 in 7.2% (280/3914), re-
spectively. Baseline clinical characteristics including
demographic data, laboratory findings and FRS in four
groups are presented in Table 1.
“Non-calcified” plaque on CCTA
Age (56 ± 9 year vs. 52 ± 10 year, p <0.001), diastolic BP
(75 ± 10 mmHg vs. 72 ± 10 mmHg, p <0.001) in demo-
graphic data, and plasma LDL-cholesterol (129 ±
30 mg/dL vs. 125 ± 32 mg/dL, p = 0.031), fasting blood
glucose (102 ± 34 mg/dL vs. 94 ± 21 mg/dL, p <0.001)
and HbA1c (6.0 ± 1.4% vs. 5.6 ± 0.7%, p <0.001)
concentration in laboratory findings showed a signifi-
cant difference between group 2 and 1, respectively
(Table 1). However, there were no significant gender
difference (group 1, M : F = 887: 1265; group 2, M : F =
98 : 102; p = 0.067) and in FRS (6.4 ± 6.4% vs. 6.5 ±
4.6%, p = 0.869; Fig. 2a) between group 2 and 1.
“Calcified” plaque on CCTA
Age (57 ± 9 year vs. 52 ± 10 year, p <0.001), BMI (25.8 ±
4.1 kg/m2 vs. 24.6 ± 3.7 kg/m2, p <0.001), systolic BP
(127 ± 17 mmHg vs. 122 ± 14 mmHg, p <0.001), and dia-
stolic BP (76 ± 11 mmHg vs. 72 ± 10 mmHg, p <0.001)
Table 1 Baseline clinical and laboratory characteristics










Age, year *‡∥ 52 ± 10 56 ± 9 57 ± 9 56 ± 9 <0.001
Gender, male, n (%) ¶ 887 (41.2) 98 (49.0) 151 (47.3) 199 (71.1) 0.003
Hypertension, n (%) ¶ 567 (26.3) 57 (28.5) 18 (5.6) 142 (50.7) 0.949
Diabetes mellitus, n (%) 191 (8.9) 30 (15.0) 9 (2.8) 27 (9.6) 0.359
Dyslipidemia, n (%) 284 (13.2) 26 (13.0) 15 (4.7) 44 (15.7) 0.569
Familial history of CVA, n (%) 573 (26.6) 61 (30.5) 24 (7.5) 93 (33.2) 0.245
Body mass index, Kg/m2 ‡∥ 24.6 ± 3.7 24.9 ± 3.4 25.8 ± 4.1 25.6 ± 4.0 < 0.001
Systolic BP, mm Hg ‡∥ 122 ± 14 127 ± 14 127 ± 17 126 ± 13 < 0.001
Diastolic BP, mm Hg *‡∥ 72 ± 10 75 ± 10 76 ± 11 75 ± 10 < 0.001
Heart rate, beats per minute * 64 ± 10 65 ± 11 65 ± 10 64 ± 11 0.054
Smoking status, n (%) 94 (4.4) 6 (3.0) 13 (0.9) 78 (27.9) 0.003
Laboratory findings
Total cholesterol, mg/dL 204 ± 36 198 ± 39 203 ± 40 204 ± 35 0.416
Triglyceride, mg/dL∥ 116 ± 81 126 ± 99 120 ± 79 133 ± 79 0.045
HDL-C, mg/dL ‡∥ 52 ± 13 51 ± 11 50 ± 12 49 ± 11 0.006
LDL-C, mg/dL * 125 ± 32 129 ± 30 125 ± 36 124 ± 33 0.313
Fasting blood glucose, mg/dL *‡ 94 ± 21 102 ± 34 101 ± 24 99 ± 21 0.008
HbA1c,% *‡ 5.6 ± 0.7 6.0 ± 1.4 5.9 ± 0.8 5.7 ± 0.6 < 0.001
C reactive protein, mg/dL 0.16 ± 0.41 0.16 ± 0.27 0.19 ± 0.32 0.18 ± 0.30 0.521
Data are expressed as means ± standard deviation or number of patients (percentage)
Group 1, CACS = 0 & normal CCTA; Group 2, CACS = 0 & CCTA of minimal disease (luminal diameter < 25%); Group 3, CACS >0 & normal CCTA (CACS rage: 0.42–7.9);
Group 4, CACS ≤ 10 or CCTA of minimal disease (luminal diameter < 25%) [16–18].
* p < 0.05, p values was analyzed using Student’s t-test for the relationship between group 1 and 2
† p < 0.05, p value was analyzed using chi-square test for the relationship between group 1 and 2
‡ p < 0.05, p value was analyzed using Student’s t-test for the relationship between group 1 and 3
§ p <0.05, p value was analyzed using chi-square test for the relationship between group 1 and 3
∥ p < 0.05, p value was analyzed using Student’s t-test for the relationship between group 1 and 4
¶ p <0.05, p value was analyzed using chi-square test for the relationship between group 1 and 4
CVA cerebrovascular accidents, BP blood pressure, HDL-cholesterol high density lipoprotein cholesterol, LDL-cholesterol low density lipoprotein cholesterol
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in demographic data, and plasma fasting blood glucose
(101 ± 24 mg/dL vs. 94 ± 21 mg/dL, p = 0.001) and
HbA1c (5.9 ± 0.8% vs. 5.6 ± 0.7%, p <0.001) concentra-
tion in laboratory findings showed a significant differ-
ence between group 3 and 1, respectively (Table 1).
Plasma HDL-cholesterol (50 ± 12 mg/dL vs. 52 ± 13 mg/
dL, p = 0.016) showed a significant lower in group 3
greater than group 1 (Table 1). However, there was no a
significant gender difference (group 1, M : F = 887 :
1265; group 3, M : F = 151 : 168; p = 0.062) and in FRS
(6.4 ± 6.4% vs. 8.2 ± 5.8%, p = 0.105; Fig. 2a) between
group 1 and 3, respectively.
“Mixed” plaque on CCTA
Age (56 ± 9 year vs. 52 ± 10 year, p <0.001), male ratio
(71.1% vs. 41.2%; p = 0.012), prevalence of hypertension
(71.1% vs. 26.3%; p = 0.038), BMI (25.6 ± 4.0 kg/m2 vs.
24.6 ± 3.7 kg/m2, p = 0.001), systolic BP (126 ± 13 mmHg
vs. 122 ± 14 mmHg, p = 0.001), and diastolic BP (75 ±
10 mmHg vs. 72 ± 10 mmHg, p <0.001) in demographic
data, and triglyceride (133 ± 79 mg/dL vs. 116 ± 81 mg/
dL, p = 0.017) concentration in laboratory findings
showed a significant higher in group 4 greater than
group 1, respectively (Table 1). Plasma HDL-cholesterol
(49 ± 11 mg/dL vs. 52 ± 13 mg/dL, p = 0.017) showed a
significant lower in group 4 greater than group 1
(Table 1). However, there was no a significant difference
in FRS (6.4 ± 6.4% vs. 7.7 ± 5.7%, p = 0.057; Fig. 2a) be-
tween group 1 and 4.
FRS according to the plaque pattern on CCTA
There was no difference of FRS among the groups (6.4
± 6.4% vs. 6.5 ± 4.6% vs. 8.2 ± 5.8% vs. 7.7 ± 5.7, p = 0.086;
Fig. 2a). From the analysis for FRS using unpaired t-test,
there was no difference in FRS [(group 1 : 2 = 6.4 ± 6.4%:
6.5 ± 4.6%, p = 0.639) vs. (group 1 : 3 = 6.4 ± 6.4%: 8.2 ±
5.8%, p = 0.053) vs. (group 1 : 4 = 6.4 ± 6.4%: 7.7 ± 5.7%,
p = 0.057), respectively; Fig. 2a].
In group 1, age (r = 0.433, p <0.001), BMI (r = 0.221,
p <0.001), systolic BP (r = 0.265, p <0.001), and dia-
stolic BP (r = 0.320, p <0.001) in demographic data
and plasma total cholesterol (r = 0.292, p <0.001), tri-
glyceride (r= 0.324, p <0.001), HDL-cholesterol (r= -0.314,
p <0.001), LDL-cholesterol (r= 0.315, p <0.001), and fasting
blood glucose (r= 0.138, p = 0.017) in laboratory findings
was closely related FRS, respectively (Table 2). In group 2,
there was no cardiovascular risk factor related FRS (Table 2).
In group 3, age (r= 0.562, p <0.001) in demographic data
and plasma total cholesterol (r= 0.384, p= 0.030), triglycer-
ide (r= 0.420, p= 0.017) in laboratory findings was closely
related FRS, respectively (Table 2).
According to the NCEP guidelines, the prevalence of
each subgroup for 10-year CHD risk was low-risk in
48.7% (1906/3914), intermediate-risk in 21.2% (829/
3914), and high-risk group 5.5% (216/3914), respectively
(Fig. 2b) However, there was no difference in FRS of the
subgroup, including low-risk (group 1: 2: 3: 4 = 3.6%:
4.5%: 4.1%: 4.0%, p = 0.408), intermediate-risk (group 1:
2: 3: 4 = 12.6%: 11.1%: 12.0%: 12.8%, p = 0.150) and high-
risk subgroup (group 1: 2: 3: 4 = 22.8%: 21.8%: 20.0%:
22.5%, p = 0.596), respectively (Fig. 2b).
Independent cardiovascular risks
In multivariate logistic regression analysis for the cardio-
vascular risks, HbA1c (OR = 2.285; 95% CI = 1.029–
5.071; p = 0.042) was an independent factor associated
with group 2 (so called “non-calcified or soft” plaque);
age (OR = 1.115; 95% CI = 1.034–1.202; p = 0.005) and
smoking status (OR = 3.386 ; 95% CI = 1.124–10.202; p =
Fig. 2 Comparison of Framingham risk score among the groups (a) and according to the risk stratification of Framingham risk score (b). Group 1,
CACS = 0 & normal CCTA; Group 2, CACS = 0 & CCTA of minimal disease (luminal diameter <25%); Group 3, CACS >0 & normal CCTA (CACS rage:
0.42–7.9); Group 4, CACS≤ 10 or CCTA of minimal disease (luminal diameter <25%) [16–18]. *, p value was analyzed using Student’s t-test for the
relationship between two groups; †, p value was analyzed using ANOVA test for the relationship among the four groups. CACS, coronary artery
calcium score; CCTA, coronary computed tomographic angiography
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0.030) were independent factors associated with group 3
(so called “calcified” plaque); and age (OR = 1.054; 95% CI
= 1.011–1.099; p = 0.014) and presence of hypertension
(OR = 3.087; 95% CI = 1.536–6.202; p = 0.001) were inde-
pendent factors associated with group 4 (so called “mixed”
plaque), respectively (Table 3).
Discussion
The accumulation of atherosclerotic plaque without
significant coronary stenosis happens over many years
prior to acute cardiovascular events, including myocar-
dial infarction or sudden cardiac death. Furthermore,
CACS on CCTA, as a recent diagnostic tool, has been
shown to be helpful in patients with low- and
intermediate-risk who presents with atypical cardiac
symptoms [7, 8]. At the same time, effective strategies
for earlier identification of subclinical coronary athero-
sclerosis requires in healthy subjects. In the present
study, unlike previous research using CCTA in symp-
tomatic patients with significant or obstructive CAD
[13, 14], we focused on the different cardiovascular risk
factors associated with the plaque pattern on CCTA in
healthy subjects. As a result, in this single-center,
cross-sectional study of healthy subjects comparing
CCTA with FRS, our data revealed that CCTA is reli-
able and effective for the estimation of the different car-
diovascular risk factors associated with the plaque
pattern on CCTA in healthy subjects. However, to pre-
dict the presence of subclinical coronary atheroscler-
osis, further investigations are required prospective
study in larger populations via multicenter trials.
Association with FRS and the plaque pattern on CCTA
FRS or CACS on CCTA for cardiovascular risk
stratification is a useful tool. However, these tools
alone may insufficient to identify subclinical coronary
atherosclerosis in some part of the population. In
addition, the combination of FRS and CACS may
provide more accurate estimation of the risk of
cardiovascular events [24]. In our study, although our
data showed a weak correlation between FRS and
traditional cardiovascular risk factors such as older
age, obesity indicators, blood pressure and plasma
lipid profile in subjects with “normal” coronary
arteries on CCTA, there was no difference of FRS
among the groups classified according to the plaque
pattern on CCTA. As described in several previous
published studies [7, 8], these findings are particularly
consistent with the facts that CACS on CCTA in
clinical application can provide valuable prognostic
evaluation and serve as an important tool for
cardiovascular risk stratification of asymptomatic or
healthy individuals, although CACS on CCTA should
not be recommended as a tool to diagnose significant
obstructive CAD in symptomatic patients.
Difference of the plaque pattern on CCTA
In analysis for the cardiovascular risk stratification of the
development and progression of subclinical coronary
atherosclerosis and the difference of the plaque pattern
on CCTA such as “non-calcified” or “calcified” plaque,
North et al. demonstrated the role of smoking status in
the pathogenesis of “calcified” coronary plaque, similar
Table 2 Correlation coefficients between Framingham risk score and clinical variables
Total = 2951 Group 1 (n = 2152) Group 2 (n = 200) Group 3 (n = 319) Group 4 (n = 280)
r p value r p value r p value r p value
Demographic data
Age, year 0.333 < 0.001 0.124 0.573 0.562 0.002 0.112 0.449
Body mass index, Kg/m2 0.221 < 0.001 0.261 0.228 0.056 0.764 0.124 0.401
Systolic BP, mm Hg 0.265 < 0.001 0.079 0.721 0.278 0.123 0.264 0.070
Diastolic BP, mm Hg 0.320 < 0.001 0.022 0.922 0.290 0.108 0.331 0.022
Heart rate, beats per minute 0.027 0.637 0.027 0.312 0.035 0.848 0.324 0.025
Laboratory findings
Total cholesterol, mg/dL 0.292 < 0.001 0.050 0.822 0.384 0.030 0.110 0.456
Triglyceride, mg/dL 0.324 < 0.001 0.025 0.911 0.420 0.017 0.301 0.037
HDL-C, mg/dL - 0.314 < 0.001 - 0.228 0.295 - 0.175 0.339 −0.356 0.013
LDL-C, mg/dL 0.315 < 0.001 0.053 0.809 0.337 0.059 0.116 0.434
Fasting blood glucose, mg/dL 0.138 0.017 0.005 0.980 - 0.076 0.678 0.228 0.119
HemoglobinA1c,% 0.092 0.115 0.115 0.612 0.048 0.796 0.165 0.269
C reactive protein, mg/dL - 0.015 0.802 0.116 0.628 0.270 0.212 0.166 0.277
Group 1, CACS = 0 & normal CCTA; Group 2, CACS = 0 & CCTA of minimal disease (luminal diameter <25%); Group 3, CACS >0 & normal CCTA (CACS rage: 0.42–7.9);
Group 4, CACS ≤10 or CCTA of minimal disease (luminal diameter <25%) [16–18].
BP blood pressure, HDL-cholesterol high density lipoprotein cholesterol, LDL-cholesterol low density lipoprotein cholesterol
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to our result [25]. On the other hand, from the ROMI-
CAT trial as a prospective, observational cohort study,
Lehman et al. reported that smoking were independently
associated with coronary atherosclerotic plaque burden
progression on CCTA in patients with acute chest pain
over 2 years, although rate of progression is dependent
on plaque composition and may be higher for “non-
calcified” when compared to “calcified” plaque [26]. In
addition, in patients referred to the emergency department
with chest pain, Yoon et al. reported that the patients
≥50% CAD of “non-calcified” plaque on CCTA were youn-
ger and had a higher prevalence of smoking [27].
Otherwise, the present study may have an important
or interesting clinical implication in the association be-
tween HbA1c, as a key marker of diabetes control and
“non-calcified” plaque from this observation. Interest-
ingly, Hausleiter et al. demonstrated the role of “non-cal-
cified” plaque, characterized by significantly higher total
cholesterol, LDL-C, and C-reactive protein levels in pa-
tients with acute coronary syndrome [28]. Furthermore,
more recent studies suggested that effective prevention
has to be focused on the type of plaque composition
[29–31]. Nicholls et al. demonstrated that “calcified” pla-
ques are more resistant to undergoing changes in size in
response to systemic interventions targeting atheroscler-
otic risk factors. On the contrary, “non-calcified” plaque
might have a higher tendency to regress in response to
established medical therapies [29]. Several studies also
suggested that “mixed” plaque could convey a higher
coronary risk including of acute coronary syndromes
[29, 30]. Thus, to overcome these various issues and
problems for identifying subclinical coronary athero-
sclerosis, we need to conduct further research in a larger
population including of ethnic differences.
There are several limitations that our study includes
the relatively small sample size and possibility of referral
bias from one center trial. First, the proportion of sam-
ple group was lower in group 2–4 than group 1 in
present study. Second, there is a lack of knowledge
about the analysis including statin therapy and differen-
tial hormonal effects based on gender. Last, our investi-
gators suggest that prospective studies via large multi-
ethnic populations and long-term follow up are required
to determine the potential value of identifying the devel-
opment and progression of subclinical coronary athero-
sclerosis and to predict the prognosis of CHD.
Conclusions
Although there was no difference of FRS among the
groups classified according to the plaque pattern on
CCTA, our data suggest that more individualized ther-
apy for reduction of cardiovascular risks could be con-
sidered in healthy subjects.
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Table 3 Multivariate analysis
Oddi ratio 95% confidence interval p value
Independent factor associated with group 2,
so called “non-calcified or soft” plaque
Age, year 1.019 0.968–1.073 0.473
Gender, male 2.452 0.686–8.767 0.168
Systolic BP 0.977 0.918–1.039 0.455
Diastolic BP 1.052 0.973–1.137 0.201
LDL-cholesterol 1.009 0.995–1.005 0.218
Fasting blood glucose 0.980 0.947–1.015 0.260
HbA1c 2.285 1.029–5.071 0.042
Smoking status 0.988 0.352–2.773 0.981
Independent factor associated with
group 3, so called “calcified” plaque
Age, year 1.115 1.034–1.202 0.005
Gender, male 6.066 0.974–37.799 0.053
Body mass index 0.905 0.708–1.156 0.425
Systolic BP 1.039 0.985–1.095 0.159
Diastolic BP 0.982 0.919–1.049 0.593
HDL-cholesterol 1.011 0.979–1.045 0.500
Fasting blood glucose 0.994 0.970–1.018 0.593
HbA1c 1.681 0.817–3.459 0.159
Smoking status 3.386 1.124–10.202 0.030
Independent factor associated with
group 4, so called “mixed” plaque
Age, year 1.054 1.011–1.099 0.014
Gender, male 1.294 0.520–3.220 0.580
Hypertension 3.087 1.536–6.202 0.001
Body mass index 0.866 0.710–1.098 0.183
Systolic BP 1.002 0.960–1.072 0.954
Diastolic BP 1.014 0.969–1.005 0.410
Heart rate 1.027 0.993–1.061 0.119
Triglyceride 1.000 0.995–1.005 0.973
HDL-cholesterol 0.999 0.999–1.030 0.942
Fasting blood glucose 0.989 0.996–1.013 0.378
HbA1c 1.349 0.662–2.746 0.410
Smoking status 1.817 0.736–4.485 0.195
Group 2, CACS = 0 & CCTA of minimal disease (luminal diameter <25%); Group
3, CACS >0 & normal CCTA (CACS rage: 0.42–7.9); Group 4, CACS ≤10 or CCTA
of minimal disease (luminal diameter <25%) [16–18].
BP blood pressure, LDL-cholesterol low density lipoprotein cholesterol, HDL-
cholesterol high density lipoprotein cholesterol
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